This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages
Cancer Immunology, Immunotherapy Open Access 19 January 2023
-
JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Leukemia Open Access 18 May 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD . Macrophage inflammatory protein-1 alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001; 97: 3349–3353.
Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A . Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003; 123: 106–109.
Haaber J, Abildgaard N, Knudsen LM, Dahl IM, Lodahl M, Thomassen M et al. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol 2008; 140: 25–35.
Chen H, Campbell RA, Chang Y, Li M, Wang CS, Li J et al. Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. Blood 2009; 113: 1992–2002.
Padró T, Ruiz S, Bieker R, Bürger H, Steins M, Kienast J et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637–2644.
Uneda S, Hata H, Matsuno F, Harada N, Mitsuya Y, Kawano F et al. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 2003; 120: 53–55.
Abe M, Hiura K, Ozaki S, Kido S, Matsumoto T . Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. J Bone Miner Metab 2009; 27: 16–23.
Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001; 108: 1833–1841.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Roussou, M., Tasidou, A., Dimopoulos, M. et al. Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia 23, 2177–2181 (2009). https://doi.org/10.1038/leu.2009.130
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.130
This article is cited by
-
Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages
Cancer Immunology, Immunotherapy (2023)
-
Evolving cancer–niche interactions and therapeutic targets during bone metastasis
Nature Reviews Cancer (2022)
-
Monoclonal antibody Daratumumab promotes macrophage-mediated anti-myeloma phagocytic activity via engaging FC gamma receptor and activation of macrophages
Molecular and Cellular Biochemistry (2022)
-
JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Leukemia (2021)
-
Bone tissue quality in patients with monoclonal gammopathy of uncertain significance
Journal of Bone and Mineral Metabolism (2020)